Tumor-Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma.
Zongyi YangJia FengLi XiaoXi ChenYuanfei YaoYiqun LiYu TangShuai ZhangMin LuYu QianHongjin WuMing ShiPublished in: Hepatology (Baltimore, Md.) (2020)
We provide evidence that tumor-derived PGLYRP2 acts as a candidate biomarker for adequate immune response against HCC and improved patient outcomes, indicating the importance of hepatic PGLYRP2 in cancer immunosurveillance and in designing immunotherapeutic approaches.